Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96QH8
UPID:
LYZL5_HUMAN
Alternative names:
Lysozyme-like protein 5; Sperm-specific lysozyme-like protein X
Alternative UPACC:
Q96QH8; Q6UWD1
Background:
Sperm acrosome-associated protein 5, also known as Lysozyme-like protein 5 and Sperm-specific lysozyme-like protein X, plays a crucial role in the fertilization process. Its unique structure and function within the sperm acrosome highlight its importance in the successful fusion with the oocyte.
Therapeutic significance:
Understanding the role of Sperm acrosome-associated protein 5 could open doors to potential therapeutic strategies. Its pivotal role in fertilization makes it a target for addressing infertility issues.